Editorial: Barrett's Esophagus and Adenocarcinoma
Authors:
- Joel E. RichterJRJoel E. Richter
- Gary W. FalkGFGary W. Falk
- 1 September 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 23 (2) , 88-90
Abstract
The fear of cancer has evoked calls for intensive surveillance programs in Barrett's esophagus. Two evolving issues are fueling this fire: (a) the rising risk of adenocarcinoma of the esophagus over the past 20 years and (b) the coincidental increase in the recognized prevalence of Barrett's esophagus in the general population. However, these sobering statistics must be carefully weighed against the lack of adverse effects on survival and the cost of an extensive surveillance program for adenocarcinoma in Barrett's esophagus, the latter estimated at between $(300) and $(1,500) million per year. Barrett's esophagus and its associated cancer risk represent a crisis in gastroenterology. A consensus conference of leading basic and clinical scientists is needed in this area.Keywords
This publication has 8 references indexed in Scilit:
- The columnar-lined esophagus, intestinal metaplasia, and Norman BarrettGastroenterology, 1996
- Prevalence of metaplasia at the gastro-oesophageal junctionThe Lancet, 1994
- Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patientsThe Journal of Thoracic and Cardiovascular Surgery, 1994
- Rising incidence of adenocarcinoma of the esophagus and gastric cardia1991
- Prevalence of columnar-lined (Barrett's) esophagusGastroenterology, 1990
- Adenocarcinoma in Barrett's oesophagus: an overrated risk.Gut, 1989
- The Incidence of Adenocarcinoma in Columnar-Lined (Barrett's) EsophagusNew England Journal of Medicine, 1985